Avelumab plus axitinib verbetert progressievrije overleving bij niercelcarcinoom

Delen via:
ESMO 2018

Log hier in om volledige toegang te krijgen.

Login of Account maken

 

Bronnen:
Motzer RJ, Penkov K, Haanen JBAG, et al. JAVELIN Renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). ESMO 2018, abstract LBA6_PR.

Longkankersymposium 2017

jan 2017 | Longoncologie

Lees meer over Longkankersymposium 2017